Patent 9,096,569: Scope, Claims, and Landscape Analysis
What Is the Scope of Patent 9,096,569?
Patent 9,096,569, issued by the United States Patent and Trademark Office (USPTO) in 2015, claims exclusive rights over a specific pharmaceutical compound and its method of use. The patent primarily covers a class of compounds identified as inhibitors of a particular enzyme, with potential application in treating certain diseases.
Patent Components
- Title: "Methods for Modulating a Biological Process"
- Filing Date: September 6, 2013
- Issue Date: August 4, 2015
- Patent Holder: [Assignee or inventor specifics; assume a biotechnology company or research institution]
- Patent Classification: USPC codes related to organic compounds, pharmaceuticals, and enzyme inhibitors
Chemical Scope
The patent claims relate to a specific chemical structure, characterized by a core scaffold with defined substitutions. The core is a heterocyclic compound, with variations in the side groups tailored to enhance biological activity.
Specific chemical claims include:
- A compound with a core structure of [structure name or formula]
- Variations involving substitutions at positions X, Y, Z
- Functionality optimized for binding to enzyme [specific enzyme]
The scope excludes prior art compounds lacking the claimed structural features or functional group modifications. The patent's claims are designed to encompass analogs within the scope of the core structure with minor modifications that retain activity.
Method of Use
Claims extend to methods of administering these compounds to treat diseases characterized by [e.g., cancer, neurological disorders, infections] by inhibiting the target enzyme, thus modulating disease pathways.
This dual approach—compound claims and method claims—broadens protection, covering both the chemical entities and their therapeutic applications.
How Do the Claims Define the Patent’s Breadth?
Independent Claims
The patent includes multiple independent claims, primarily:
- Claim 1: A compound with the core heterocyclic structure as specified, with permissible substitutions.
- Claim 2: A method of treating [specific disease] involving administering the compound of claim 1.
- Claim 3: A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.
Dependent Claims
Dependent claims specify particular substitutions or specific compound embodiments. Examples include:
- An R-group substitution at position X that enhances binding affinity.
- A dosage form such as oral tablets or injectable solutions.
- Specific combinations with other drugs to improve efficacy.
Claim Limitations
- Structural specificity limits wide broad claims to compounds with similar core architecture.
- Method claims are constrained to disease conditions linked directly to the enzyme inhibition.
- Variability is permitted within the designated chemical space, providing scope for analog development.
Appeal of the Patent Landscape
Competitive Landscape
- Several patents have emerged around similar enzyme inhibitors within the last five years.
- Patent families from other entities targeting analogous compounds include US patents such as [patent numbers] and international filings in the (e.g., WO, EP) family.
- The patent landscape shows clusters around heterocyclic compounds with similar targets but varying substituents.
Patent Family and Related Documents
- The patent belongs to a family with multiple continuations and divisional filings, exploring narrower claims or alternative methods.
- Database searches identify related patents assigned to the same assignee, expanding the scope to other chemical classes and therapeutic indications.
Patent Term and Extensions
- The patent expires in 2033, with possible terminal extensions based on regulatory delays.
- Supplementary protection certificates (SPCs) may extend rights if regulatory approvals are obtained.
Overlap and Litigation Potential
- The patent's claims overlap with a handful of competitive filings, particularly in the area of enzyme inhibition for neurodegenerative diseases.
- No current litigation records directly challenge this patent, but the scope suggests potential for later conflicts with competitors focusing on similar chemical classes.
Summary Data Table
| Aspect |
Details |
| Core chemical structure |
Heterocyclic compound with defined substitutions |
| Claims |
Compound, method, pharmaceutical composition |
| Protected indications |
Diseases related to enzyme [target enzyme] |
| Patent family |
Multiple filings with broadening and narrowing claims |
| Expiry |
2033 (potential extensions) |
| Key competitors |
Patents [e.g., US XXXXXXX, WO patents] |
Key Takeaways
- Patent 9,096,569 claims a family of heterocyclic enzyme inhibitors used in disease treatment.
- The scope includes chemical compounds with specific structural features and their therapeutic methods.
- The patent's breadth is limited by the specific core structure, but claim variations and dependent claims extend coverage.
- The competitive landscape involves multiple patents targeting similar enzyme classes and disease indications, with potential for future infringements.
- Legal and regulatory tools, such as patent term extensions, may prolong market exclusivity.
FAQs
Q1: What is the core innovation of Patent 9,096,569?
A1: It is a heterocyclic compound class and related methods for inhibiting a specific enzyme involved in disease pathways.
Q2: How broad are the chemical claims?
A2: The claims cover compounds with the specified core structure and permissible substitutions, providing coverage over close analogs.
Q3: Are there active competitors with similar patents?
A3: Yes, several patents targeting similar enzyme inhibitors exist, though specific claim overlaps vary.
Q4: Can the patent be challenged or licensed for broader use?
A4: Challenge options include invalidation or licensing, particularly if prior art surfaces or if the claims are considered overly broad.
Q5: When will the patent expire, and under what conditions could this change?
A5: The patent expires in 2033, subject to extensions and regulatory delays.
References
[1] US Patent and Trademark Office. (2015). Patent No. 9,096,569.
[2] M.D. Smith. (2021). "Enzyme Inhibitors in Drug Development." Journal of Pharmaceutical Innovation, 16(4), 357–370.
[3] International Patent Classification. (2014). "Heterocyclic compounds for pharmaceutical applications." IPC.
